Supplementary Data 1 from Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study

Ahn et al. (Wed,) studied this question.

www.synapsesocial.com/papers/68e6a13db6db643587624d5f — DOI: https://doi.org/10.1158/1078-0432.25826742.v1

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Supplementary Data 1 from Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of <i>KRAS</i>-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study· 2024
2. Data from Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of <i>KRAS</i>-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study· 2024
3. Abstract 2031: A phase 1b/2 clinical study of onvansertib in combination with FOLFIRI/bevacizumab revealed a new role of PLK1 in regulating the hypoxia pathway in KRAS-mutant colorectal cancer· 2024
4. Abstract CT275: A phase 2, randomized, open-label study of onvansertib in combination with standard-of-care (SoC) versus SoC alone for first-line treatment of RAS-mutant metastatic colorectal cancer (mCRC)· 2024
5. Supplementary Figure S3 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer· 2024